All In Biotech

Drug Trial Radar · NCT06251180

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jun 30, 2027

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Feb 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\].

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

  • RocbrutinibDrug

    orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

  • RituximabBiological

    375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

  • CyclophosphamideDrug

    750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

  • doxorubicinDrug

    50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

  • VincristinDrug

    1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

  • PrednisoneDrug

    100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: Up to 21 days after the initial dose
  2. Recommended DoseTime frame: Up to 1.5 years
  3. Incidence of AEsTime frame: From first dose of study drug to 28 days after the last dose of study drugs
  4. Incidence of clinically significant laboratory abnormalitiesTime frame: From first dose of study drug to 28 days after last dose of study drug
  5. Cmax of RocbrutinibTime frame: Up to 24 hours post dose
  6. Tmax of RocbrutinibTime frame: Up to 24 hours post dose
  7. T1/2 of RocbrutinibTime frame: Up to 24 hours post dose
  8. AUC0-t of RocbrutinibTime frame: Up to 24 hours post dose
  9. CL/F of RocbrutinibTime frame: Up to 24 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.